Based on the metabolic reprogramming of oxidative phosphorylation mechanisms, we confirmed that inhibiting Gal-3 could effectively diminish the dependence of pancreatic cancer on gemcitabine, effectively counteract tumor growth, and reduce related adverse drug reactions. Here, LGALS3 is linked to familial pancreatic carcinoma.